The trajectory of companies tied to Viagra's legacy presents a challenging investment picture . While the initial success generated substantial gains, generic alternatives have significantly impacted sales . Investing in associated pharmaceutical firms now requires a discerning assessment of patent protection , evolving medical trends , and the pot